By Dr. Roynny Sanchez Gil, MD
Medical Contributor, WeightLossPills.com
The question I hear more than almost any other from patients starting semaglutide is some version of this: “How long is it going to take?” They’ve read the studies, watched the before-and-after videos, and they are ready. What they are not ready for is the gap between starting a medication and actually seeing the scale move — a gap that, in my clinical experience, is responsible for a substantial number of people abandoning a treatment that would have worked if they had stayed with it.
The timeline for GLP-1 therapy is specific and physiologically predictable. Understanding it in advance changes the patient experience from one of uncertainty and doubt into one of informed waiting. And informed waiting is a very different thing from wondering whether something is wrong.
Why the First Dose Doesn’t Do Much
When a patient takes their first Ozempic injection at the standard starting dose of 0.25 mg, the pharmacological effect is real but deliberately modest. That starting dose is not a therapeutic dose — it is a tolerability dose. The clinical development of semaglutide established that ramping patients up slowly dramatically reduces the gastrointestinal side effects that cause early discontinuation, so the initial weeks are essentially a period of physiological acclimation rather than active treatment at full effect.
This is a point I try to make explicitly to every new patient, because the expectation mismatch otherwise can be severe. A patient who expects to feel appetite suppression within days of their first injection and doesn’t is not experiencing a treatment failure — they’re experiencing pharmacology as designed. The drug reaches meaningful steady-state concentrations only after multiple weeks of dose escalation, and the full therapeutic effect at a given dose emerges gradually as receptor occupancy increases and downstream signaling pathways stabilize.
Weeks One Through Four: The Adjustment
In the first month, most patients notice some changes even at the lower doses, but the predominant experience is often gastrointestinal adjustment rather than meaningful appetite suppression. Nausea is the most common complaint, and it tends to be worst in the day or two following each injection. This is not a signal that the medication isn’t working or that a patient’s body is rejecting it — it is an expected consequence of GLP-1 receptor activation on the gut, which slows gastric emptying and can temporarily heighten nausea signals in susceptible individuals.
What I advise during this period is specific: eat smaller meals than you’re used to, avoid high-fat or highly processed foods that already linger in the stomach, and do not push through nausea by eating more to “coat the stomach” as you might with other medications. The nausea is typically most manageable when you simply eat less at each sitting — which happens to align perfectly with what the medication is trying to accomplish.
Some patients report mild appetite changes in these early weeks, a slight reduction in the urgency around meals, a little less interest in snacking. When that happens, I encourage patients to take it as a signal that the medication is beginning to work rather than treating it as something to counteract. But I also caution them not to read too much into the absence of that signal. Individual variation in early response is wide, and the absence of dramatic appetite suppression at week two does not predict anything meaningful about how the treatment will unfold at week twelve.
Weeks Five Through Eight: The Mechanism Becomes Clearer
As patients move through the dose escalation — typically from 0.25 mg to 0.5 mg around week five — the picture usually shifts. At this point, the physiological effects that actually drive weight loss start becoming more noticeable to the patient themselves. GLP-1 receptor agonists work through several converging mechanisms: they slow gastric emptying so that food stays in the stomach longer and satiety signals persist, they act on hypothalamic receptors that regulate hunger and reward pathways, and they reduce the pleasure response associated with highly palatable food.
That last point often surprises patients. They’ll describe it as food “just not sounding good” in the same way it used to, or noticing that they finish half a restaurant meal and genuinely don’t want the rest — not because they’re forcing willpower, but because the biological drive to keep eating has been attenuated. This is different from traditional caloric restriction, where hunger is constantly pushing back against a patient’s deliberate effort to eat less. With adequate GLP-1 receptor activation, the hunger itself is reduced.
Weight loss, when it starts appearing on the scale at this stage, is typically modest — two to four pounds for most patients, sometimes a bit more depending on baseline weight and other factors. This is not the kind of number that generates excitement after five or six weeks of injections, which is exactly why the attrition risk is high right here. Patients who came in expecting rapid transformation may feel that the results are not proportional to the effort. My job at this point is to explain that what they’re seeing is not the plateau — it’s the early slope.
Months Two Through Four: Where Real Progress Accumulates
The clinical trials that established semaglutide’s efficacy as a weight loss treatment measured outcomes at 68 weeks. This is not an arbitrary endpoint. The drug’s effect on body weight is cumulative and progressive, and the greatest rate of change typically occurs not in the first month but somewhere between months two and six. Patients who have tolerated the titration period and reached the 1 mg dose — or are moving toward higher doses for those on the Wegovy formulation — are entering the window where the mechanism is functioning at something closer to full effect.
What this looks like practically is that the rate of weight loss often accelerates after that initial sluggish period. Patients who lost four pounds in their first five weeks sometimes find themselves down another eight or ten pounds over the following six to eight weeks. This is not a fluke or a sudden surge — it reflects the drug reaching a steady state at therapeutic concentrations, combined with the behavioral changes that tend to compound when appetite suppression is more consistent and patients begin rebuilding their relationship with food.
There is also something that happens cognitively during this period that I think is underappreciated. Patients start to realize that the mental noise around food — the constant low-level negotiation between craving and restraint that occupies so much bandwidth for people who struggle with weight — has quieted. They stop thinking about their next meal before they’ve finished the current one. They notice they’re leaving food on the plate without much thought. These are not trivial changes. They represent a shift in the neurobiological experience of eating that no amount of dietary counseling alone can reliably produce.
Why Impatience Is the Drug’s Biggest Competitor
I have had patients who stopped semaglutide at week six because they had only lost five pounds and felt the medication “wasn’t working.” At week six, on a 0.25 mg starting dose, with a full titration schedule ahead of them, they quit. And when they come back months later asking about starting again, I try to explain — without making them feel foolish, because nothing about their reasoning was unreasonable given what they expected — that they discontinued before the treatment had a legitimate chance to perform.
The problem is partly how these medications are marketed and discussed in general media, where the stories are the dramatic ones. The patient who loses fifty pounds in a year. The celebrity transformation. These are not fabrications, but they represent the upper range of the distribution, not the average experience, and they compress the timeline in a way that creates unrealistic benchmarks for early follow-up appointments.
What I try to establish with every patient before they start is a simple principle: evaluate this medication at twelve to sixteen weeks, not at four. If at sixteen weeks, on an adequate dose, with reasonable adherence, a patient has seen essentially no change in weight or appetite, then we have a real clinical conversation about whether GLP-1 therapy is the right fit for them or whether something else is affecting their response. That conversation should happen — but it should happen with data, not with an abandonment at week six based on a timeline that was never realistic.
Reading Your Body’s Signals Correctly
One thing I emphasize is helping patients distinguish between signals that something is wrong and signals that the medication is working exactly as designed. Nausea in the first several weeks is expected — it is not a sign that the drug disagrees with a patient’s biology in some fundamental way. Constipation, which a meaningful percentage of patients experience, is a direct consequence of slowed gut motility and should be managed proactively rather than interpreted as failure. A slower pace of weight loss in month one compared to month three is pharmacologically predicted, not evidence of individual resistance.
The signals worth paying attention to — the ones that warrant contacting a physician rather than waiting — are different in character. Severe or persistent vomiting that doesn’t settle after the first week or two following a dose increase. Signs of dehydration. Significant abdominal pain, particularly if it radiates to the back. These warrant evaluation and in some cases a dose reduction or temporary hold, not a silent decision to stop the medication entirely and not mention it at the next appointment.
The relationship between a patient and their prescribing physician during GLP-1 therapy functions much better when both parties are communicating about what’s actually happening. A patient who quietly stops taking the medication because the nausea was uncomfortable and the weight loss wasn’t coming fast enough has lost an opportunity, and so has the physician who might have helped them problem-solve through it. The timeline for this treatment is long enough that the patient-physician relationship needs to be active rather than passive to work well.
The Investment and the Return
What I want patients to understand, before they take their first injection, is that the timeline for GLP-1 therapy is not a design flaw — it is a design feature. The deliberate titration protects against side effects that would otherwise cause far more people to discontinue. The progressive accumulation of effect reflects how the drug actually works at a mechanistic level, not a delay that could be engineered away with a higher starting dose.
The patients who do best with semaglutide are not necessarily the ones who respond most quickly in the first few weeks. They are the ones who stay with the treatment long enough for it to demonstrate what it can actually do, who communicate honestly with their physicians when they hit difficult patches, and who approach the early weeks as a calibration period rather than an audition the drug needs to pass in the first month. That framing doesn’t make the nausea more comfortable or the early weigh-ins less frustrating. But it replaces uncertainty with a roadmap, and a roadmap changes what patience feels like.
Dr. Roynny Sanchez Gil, MD, is a board-certified physician and medical contributor at WeightLossPills.com, where she specializes in GLP-1 therapy, metabolic health, and obesity medicine.